Cystic Fibrosis News Today Daily Digest

Cystic Fibrosis Weekly Update Contents: Organoid-Based Personalized Medicine Trial Enrollment Complete CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says Organoid-Based Personalized Medicine Trial Enrollment Complete Feb 28, 2020 07:00 am | Marisa Wexler MS Enrollment is complete for a European initiative to test an organoid-based, personalized-medicine approach to treating cystic fibrosis, with the first trial starting later this year, said Proteostasis Therapeutics (PTI) and CF Europe. The Human Individualized Therapy of CF (HIT-CF) initiative will test PTI drug combinations through the company’s CHOICES clinical trial, which will be the first […] The post Organoid-Based Personalized Medicine Trial Enrollment Complete appeared first on Cystic Fibrosis News Today. Read More CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says Feb 27, 2020 07:00 am | Patricia Inacio, PhD Amplifiers, a potential new class of therapies that modify CFTR — the protein whose defects cause cystic fibrosis (CF) — do so by stabilizing the template used for its production so the protein works better in cells and there’s more of it, a study into the mechanisms of amplifiers reported. Specifically, this groups of CFTR modulators work […] The post CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says appeared first on Cystic Fibrosis News Today. Read More   Recent News Advice on Starting Nonprofit Groups for Rare and Other Diseases Focus of NORD Webinar UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December Being Sick Doesn’t Give Me a Free Pass to Be Disrespectful Israeli CF Group Lobbies for Trikafta’s Inclusion in National Health Basket This Is What Makes Me Rare